Search

Your search keyword '"Mittereder, Lara"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Mittereder, Lara" Remove constraint Author: "Mittereder, Lara"
47 results on '"Mittereder, Lara"'

Search Results

1. Multiple genetic loci influence vaccine-induced protection against Mycobacterium tuberculosis in genetically diverse mice

2. Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis Infection In Vivo by a Mechanism Dependent on T Lymphocytes

7. Mycobacterium tuberculosis Induces Irg1 in Murine Macrophages by a Pathway Involving Both TLR-2 and STING/IFNAR Signaling and Requiring Bacterial Phagocytosis

13. Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?

14. A panel of correlates predicts vaccine-induced protection of rats against respiratory challenge with virulent Francisella tularensis

15. Additional file 5: Figure S5. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

16. Additional file 2: Figure S2. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

17. Additional file 8: Figure S8. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

18. Additional file 4: Figure S4. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

21. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

22. Inhibition of heme oxygenase-1 activity suppresses Mycobacterium tuberculosis infection in vivo by a mechanism dependent on T lymphocytes and IFN-γ production

28. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer

30. Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict Francisella tularensisVaccine Efficacy

31. Additional file 7: Figure S7. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

32. Additional file 12: Figure S12. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

33. Additional file 10: Figure S10. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

34. Additional file 6: Figure S6. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

35. Additional file 1: Figure S1. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

36. Additional file 9: Figure S9. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

37. Additional file 12: Figure S12. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

38. Additional file 6: Figure S6. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

39. Additional file 11: Figure S11. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

40. Additional file 11: Figure S11. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

41. Additional file 9: Figure S9. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

42. Additional file 3: Figure S3. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

43. Additional file 10: Figure S10. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

44. Additional file 7: Figure S7. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

45. Additional file 1: Figure S1. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy

46. Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosisInfection In Vivoby a Mechanism Dependent on T Lymphocytes

47. Enhancement of CD4 + T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?

Catalog

Books, media, physical & digital resources